CA
NZ
UK
AU
IND
US
Atrium Therapeutics (NASDAQ:RNA) was indicated down 3.15% in the October 9, 2026 premarket session on the screener, on a listed price of USD 8.26. The cause is a company announcement dated October 8, 2026 of a privatePlacementwith expected gross proceeds of about USD 50 …
Bristol Myers Squibb (NYSE:BMY) said a Phase 3 trial of Zenbexus showed a 51% cut in the risk of disease progression in multiple myeloma, a cancer of plasma cells in the bone marrow, according to a company release reported on October 8, 2026. The …
Clover Health (NASDAQ:CLOV) was indicated up 11.35% in the October 9, 2026 premarket session on the screener, on a listed price of USD 4.58 and premarketVolumeof 40,045 shares. The screener tags the catalyst as news, but a search found no company release, filing or …
The Centers for Medicare and Medicaid Services released its 2027 Star Ratings after the close on October 8, 2026. The ratings grade Medicare Advantage plans on quality and service from one to five stars, and plans rated 4 or higher qualify for quality bonus …
Two FDA dates are close. Enspryng, a Roche medicine, has a decision date of October 15, 2026, and the phentolamine ophthalmic solution being developed by Opus Genetics with Viatris (NASDAQ:VTRS) has a date of October 17. A third item, the Daiichi Sankyo and MerckBiologicslicense …
XORTX Therapeutics (NASDAQ:XRTX) said it has received more inquiries about commercialization and has made progress on a trial application with Health Canada, according to a company release reported around October 9, 2026. The stock rose about 22% after hours. The company's market capitalization is …
Exchange market data for October 8, 2026 showed a group of large gainers. Pacira rose about 44%, Fly-E 83%, Jianzhi Education 77%, Xiao-I 46% and Haemonetics 17.5%. Surrozen (NASDAQ:SRZN) climbed 11.2% to 27.97 and was grouped with them, alongside a 16.4% move in Cable …
Humana (NYSE:HUM) was up about 15% in premarket trading on October 9, 2026, according to a movers list. Different recaps give 12% after hours, 14.95% premarket and 16.5%, a spread that reflects timing and venue. The file does not name the catalyst, so none …
The clearest catalyst of the group is a government ratings decision. Humana (NYSE:HUM) was up 14.82% in premarket trading on October 9, 2026 on a listed price of USD 387.12 and aMarket Valueof about USD 46.49 billion. The Centers for Medicare and Medicaid Services …
Humana (NYSE:HUM) was up about 15% in premarket trading on October 9, 2026, according to a movers list. Different recaps give 12% after hours, 14.95% premarket and 16.5%, which is a spread explained by timing and venue. The file does not name the catalyst, …
Please wait processing your request...